Cingulate is a biopharmaceutical company creating a pipeline of next-generation treatments utilizing its innovative Precision Timed Release™ technology.
Kansas CIty
Joined September 2021
- Tweets110
- Following167
- Followers349
- Likes13
Being small doesn’t necessarily mean being lean.
Cingulate Chief Commercial Officer Bryan Downey shares insights from the Indegene Digital Summit on building efficient, scalable commercialization orgs for small mid-size pharma.
youtube.com/watch?v=f54U-rft…
#Cingulate #Nasdaq #CING
Why shouldn’t small pharma sell out to big pharma?
Cingulate Chairman & CEO Shane J. Schaffer shares his perspective at the Indegene Digital Summit on rethinking commercialization and product launches.
Watch the clip: youtube.com/watch?v=6XMogiDV…
#Cingulate #CING #Biopharma
ADHD can look different at different stages of life.
In a new @eHealthRadio episode, Cingulate CMO Dr. Matthew Brams joins @eHealthRadio to discuss recognizing and managing ADHD across the lifespan.
Listen: ehealthradio.podbean.com/e/a…
#ADHD #ADHDAwareness #CING
LA Weekly recently highlighted the story of Cingulate’s founders — Drs. Shane Schaffer, Matthew Brams and Raul Silva — and the vision that led to the development of our PTR™ platform and CTx-1301.
Read the story: laweekly.com/three-doctors-1…
#ADHD #CING #PTR #CTx1301
Cingulate CMO and Co-Founder Matthew Brams, MD, and Co-Founder and Chief Science Officer Raul R. Silva, MD, are featured in @medcitynews, discussing ADHD treatment and patients’ needs throughout the entire active day.
Read more: medcitynews.com/2026/09/exte…
Cingulate Chief Commercial Officer Bryan Downey will participate in the @Indegene Digital Summit Sept. 22 in Philadelphia on “Small & Mid-Size Pharma. Big-Time Launches: Reinventing the Launch Playbook.”
Full announcement: cingulate.com/news-releases/…
#Cingulate #CING #Biopharma
Cingulate Chairman & CEO @shanejschaf will speak at the @Indegene Digital Summit Sept. 22 in Philadelphia on “The SMART Launch: Rethinking Go-To-Market for Emerging Pharma Launches.”
Full announcement: cingulate.com/news-releases/…
#Cingulate #CING #Biopharma
Cingulate Chief Medical Officer Matthew Brams, MD, joined NPR’s The Spark with Asia Tabb to discuss ADHD, evolving perceptions, reducing stigma, and the importance of accurate diagnosis and evidence-based treatment.
Listen here: witf.org/2026/09/04/adhd-and…
What if ADHD treatment could keep pace with the entire active day?
In Life Science Daily News, Cingulate’s Dr. Matthew Brams and Dr. Raul Silva explore the need for ADHD treatments with rapid onset, consistent coverage, and once-daily dosing.
Read more: lifesciencedaily.news/adhd-t…
We’re proud to see Cingulate Chairman and CEO Dr. Shane J. Schaffer featured in International Business Times discussing how a child’s ADHD diagnosis may lead parents to recognize similar symptoms in themselves.
Read more: ibtimes.com/cingulate-ceo-dr…
We're pleased to share that new peer-reviewed data on CTx-1301 have been published in CNS Drugs, expanding the scientific evidence supporting our lead ADHD product candidate and PTR™ platform.
Read the announcement:
cingulate.com/news-releases/…
#ADHD #CING #CTx1301 #Biopharma
We're proud to be featured in @TheStreet, highlighting Cingulate, CEO Shane @shanejschaf and our Precision Timed Release™ (PTR™) platform. Learn how we're advancing innovation in ADHD treatment:
thestreet.com/crypto/newsroo… #ADHD #Biotech
Exciting News from Cingulate: We’ve received a $4.3M PDUFA fee waiver from the FDA ahead of our imminent NDA submission for CTx-1301, our lead asset for the treatment of ADHD.
Learn more: finance.yahoo.com/news/cingu…
#CTx1301 #ADHD #FDA #PDUFA #NDA #CING #PrecisionTimedRelease #PTR
We’re excited to welcome Nilay Patel, JD as our Chief Legal Officer! Nilay brings deep legal expertise and a strategic understanding of the complexities of pharma commercialization.
#PharmaLaw #ADHD #Cingulate #Innovation #CING #Nasdaq #ADHDtreatment
finance.yahoo.com/news/cingu…
📢 Stonegate Capital Partners has initiated coverage on Cingulate (NASDAQ: CING) with a valuation range of $13.96–$26.96.
Read the announcement and full report: finance.yahoo.com/news/stone…
#CING #ADHD #CTX1301 #NDASubmission #StonegateCapitalPartners
#ICMYI: Congress held a key hearing this week on strengthening U.S. manufacturing and supply chain security. 🇺🇸
youtube.com/watch?v=eXkAOKwv…
CING proudly supports onshoring and ensuring patient access to ADHD meds.
#adhd #cing #SupplyChainSecurity #onshoring
#ICMYI Cingulate CEO Shane Schaffer outlines CING’s plans to commercialize CTx-1301 and explains why Indegene is the perfect partner to bring CING’s lead ADHD asset to market.
#Cingulate #CING #Commercialization #ADHD
youtube.com/watch?v=JLfjj5lO…
What does an ADHD diagnosis mean to you? Cingulate CEO Shane Schaffer explores the wide spectrum of those living with ADHD and the unique paths they take on their journey.
#ADHD #CING #Cingulate #Nasdaq
youtu.be/-MPXRIvbvwY
#ICYM : Cingulate announced phase 3 pediatric efficacy results for CTX-1301. CEO Shane Schaffer joined Zacks analyst John Vandermosten on the Unboxing Biotechpodcast.
#Cingulate #biotech #efficacyresults #CING #Nasdaq
youtu.be/trHIjzvRAvs